News Releases

Jan 05, 2023
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
Products
Dec 08, 2022
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Products
Nov 29, 2022
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Products
Nov 17, 2022
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Products
Nov 14, 2022
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
Products
Nov 10, 2022
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
Products
Nov 03, 2022
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Products
Nov 01, 2022
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
Pipeline
Aug 31, 2022
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
Products
Aug 16, 2022
Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
Products
Jul 12, 2022
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial
Products
Jun 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Pipeline
Apr 26, 2022
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment
Products
Mar 14, 2022
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Corporate
Mar 11, 2022
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Products